Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Focused Fund median (29 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 26 Aug 2021 – 20 Aug 2026, limited by UTI Focused Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | UTI Focused Fund | Nifty 500 |
|---|---|---|
| 26 Aug 2021 | ₹100.00 | ₹100.00 |
| 25 Jan 2022 | ₹99.35 | ₹105.14 |
| 25 Jun 2022 | ₹90.74 | ₹94.44 |
| 24 Nov 2022 | ₹104.49 | ₹111.16 |
| 25 Apr 2023 | ₹100.67 | ₹106.02 |
| 23 Sep 2023 | ₹117.97 | ₹122.36 |
| 22 Feb 2024 | ₹133.50 | ₹143.79 |
| 23 Jul 2024 | ₹154.53 | ₹162.08 |
| 21 Dec 2024 | ₹148.28 | ₹158.22 |
| 22 May 2025 | ₹151.95 | ₹160.17 |
| 21 Oct 2025 | ₹158.76 | ₹168.42 |
| 21 Mar 2026 | ₹140.46 | ₹151.19 |
| 20 Aug 2026 | ₹157.71 | ₹166.68 |
| Metric | UTI · Regular · IDCW NAV ₹15.78 Very High risk ★★★★☆ | Category median Focused Fund · 29 funds |
|---|---|---|
| +1.43% | -3.17% | |
| +11.38% | +8.26% | |
| +9.57% | +7.82% | |
| — | +4.45% | |
| +9.57% | +9.57% | |
| +9.88% | — | |
| +14.44% | +10.33% | |
| — | +9.22% | |
| — | +4.79% | |
| Risk | ||
| 13.37% | 15.50% | |
| 0.36 | 0.15 | |
| 0.51 | 0.20 | |
| -19.77% | -37.59% | |
| Nifty 500 | — | |
| -0.36% | -2.26% | |
| 0.93 | 0.97 | |
| 96.7% | 87.5% | |
| 99.1% | 100.3% | |
| 2.27% | 2.23% | |
| ₹2,383Cr | ₹2,383Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 60% | 31% | |
| Vishal Chopda | — | |
| 26 Aug 2021 | — | |
| 29 | — | |
| 53.3% | — | |
| 3.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.